Quetiapine EP Impurity N: Chemical Structure, Characterization, and Analytical Significance
Updated: Nov 3
Pharmaceutical impurity profiling is an important part of drug substance development, analytical research, and quality control. Identifying and characterizing impurities associated with an active pharmaceutical ingredient (API) helps researchers understand its chemical composition, monitor related substances, and evaluate the quality of pharmaceutical materials. Reference standards play an important role in supporting these analytical activities.
Quetiapine EP Impurity N is a recognized impurity associated with quetiapine, an atypical antipsychotic medication. Its structural features, particularly the presence of an extended piperazine-containing side chain, make it relevant to pharmaceutical impurity identification and analytical characterization.
For pharmaceutical manufacturers, analytical laboratories, and research organizations, understanding the chemical identity and analytical significance of this impurity can support impurity profiling and related-substance investigations. This article discusses its chemical structure, molecular characteristics, characterization approaches, and importance in pharmaceutical quality assessment.
Understanding Quetiapine and Its Impurity Profile
Quetiapine is an atypical antipsychotic belonging to the dibenzothiazepine chemical class. It is used in the treatment of certain psychiatric conditions and is available in different pharmaceutical formulations.
During API synthesis, purification, processing, and storage, pharmaceutical substances may contain related compounds arising from starting materials, intermediates, process-related reactions, or degradation pathways. These compounds require appropriate analytical assessment to establish their identity and monitor their presence.
Quetiapine EP Impurity N is associated with the chemical structure of quetiapine and is identified as a specific related impurity. Its identification is particularly relevant when laboratories investigate the composition of quetiapine-related materials and develop analytical procedures for impurity monitoring.
Chemical Structure and Molecular Characteristics
Quetiapine EP Impurity N has a distinct molecular structure containing a dibenzothiazepine moiety connected to an extended side chain incorporating two piperazine rings and ether linkages.
The reported chemical name is:
2-[2-[4-[2-[2-[4-(Dibenzo[b,f][1,4]thiazepin-11-yl)piperazin-1-yl]ethoxy]ethyl]piperazin-1-yl]ethoxy]ethanol.
The commonly reported molecular identification details are:
Product Name: Quetiapine EP Impurity N
CAS Number: 1800291-86-4
Molecular Formula: C₂₉H₄₁N₅O₃S
Molecular Weight: Approximately 539.73 g/mol
Chemical Class: Quetiapine-related piperazine-containing compound
The structure contains several chemically significant functional features. The dibenzothiazepine ring system provides the characteristic aromatic heterocyclic framework, while the piperazine groups contribute nitrogen-containing cyclic structures. Ether linkages connect the different sections of the molecule, and the terminal hydroxy group adds another functional characteristic.
These structural features provide useful information for understanding its chromatographic behaviour, molecular identification, and spectroscopic characterization. The free-base identity should also be distinguished from hydrochloride salt forms, which may have separate CAS numbers and different molecular weights.
Characterization and Identification of Quetiapine EP Impurity N
Characterization involves examining the molecular and physicochemical properties of an impurity to establish its identity and distinguish it from the parent API and other related compounds.
Several analytical techniques can support the investigation of Quetiapine EP Impurity N.
1. High-Performance Liquid Chromatography (HPLC)
HPLC is widely used in pharmaceutical analysis for separating active ingredients from related substances. It can help evaluate the chromatographic behaviour of Quetiapine EP Impurity N and assess its separation from other components in a sample.
A suitable analytical procedure should consider stationary-phase selection, mobile-phase composition, detection conditions, and sample preparation. The actual method must be established and evaluated for the intended analytical purpose.
2. Liquid Chromatography–Mass Spectrometry (LC-MS)
LC-MS combines chromatographic separation with mass-based detection. It can provide valuable information for investigating the molecular identity of Quetiapine EP Impurity N.
The observed mass-to-charge ratio, together with appropriate fragmentation information, can support structural assessment and help distinguish related compounds with different molecular characteristics.
3. Nuclear Magnetic Resonance (NMR) Spectroscopy
NMR spectroscopy provides structural information based on the chemical environments of hydrogen and carbon atoms.
¹H NMR: Helps examine aromatic, aliphatic, piperazine, ether-linked, and hydroxyl-associated proton environments.
¹³C NMR: Provides information about the carbon framework and supports the assessment of the molecular structure.
These techniques can be particularly useful when confirming the identity of synthesized impurity reference materials.
4. Chromatographic Purity Assessment
HPLC-based purity assessment can help determine the relative chromatographic composition of a reference material under specified analytical conditions.
However, chromatographic area percentage should not automatically be interpreted as absolute chemical purity. Appropriate reference materials, analytical conditions, and complementary characterization data are important for reliable interpretation.
Origin and Formation Considerations
Understanding the possible origin of an impurity is an important aspect of pharmaceutical process development. Related substances may originate from different stages of API manufacturing, including chemical synthesis, intermediate processing, purification, and subsequent handling.
For Quetiapine EP Impurity N, its extended dipiperazine diether structure provides a useful structural basis for investigating its relationship with quetiapine chemistry. However, its precise formation pathway should not be assumed without supporting process-specific evidence.
Analytical researchers may investigate potential sources by examining synthesis intermediates, reaction conditions, starting-material quality, and process-related samples. Comparing the impurity's analytical profile with suitable reference material can help establish whether the compound is present in the investigated sample.
Such investigations can contribute to process understanding and support the development of appropriate impurity-control strategies.
Analytical Significance in Pharmaceutical Quality Control
The identification of Quetiapine EP Impurity N is relevant to pharmaceutical quality assessment because reliable impurity monitoring depends on the ability to distinguish individual related compounds.
Its analytical significance can be understood through several applications:
1. Impurity Identification: A well-characterized reference material can help analytical laboratories compare chromatographic and spectroscopic data when investigating the presence of this impurity.
2. Related-Substance Analysis: Appropriate analytical methods can support the separation and monitoring of Quetiapine EP Impurity N alongside other related substances.
3. Analytical Method Development: Reference materials can assist researchers in evaluating chromatographic separation, detection conditions, and method suitability for the intended analytical application.
4. Quality Control Investigations: Comparing sample responses against a suitable reference material can support investigations into API composition and manufacturing consistency.
5. Stability-Related Research: Analytical monitoring during stability investigations may help researchers evaluate changes in the impurity profile over time. The presence or formation of this particular impurity must be established experimentally rather than presumed.
Importance of Pharmaceutical Impurity Reference Standards
Pharmaceutical impurity reference standards are essential resources for analytical laboratories working with API characterization, related-substance testing, and pharmaceutical quality assessment.
A suitable reference standard provides an established material against which researchers can compare the analytical response of an investigated sample. Its value depends on reliable identification, appropriate characterization, documented analytical information, and suitable handling conditions.
For Quetiapine EP Impurity N, reference material can be useful in:
Developing and evaluating HPLC and LC-MS analytical procedures.
Supporting impurity identification and characterization.
Investigating related substances in quetiapine-containing materials.
Comparing analytical responses during method development.
Supporting research into pharmaceutical process-related impurities.
Researchers should evaluate the accompanying Certificate of Analysis (COA), identity information, assigned purity, and storage recommendations before selecting a reference material. Pharmacopoeial designation alone should not be treated as evidence of certification or official compendial reference-standard status.
Quetiapine EP Impurity N Reference Standard from Chemicea
Chemicea Pharmaceuticals Pvt. Ltd. is a chemistry-driven pharmaceutical company and contract research organization (CRO) specializing in pharmaceutical impurity reference standards, custom synthesis, and analytical research solutions.
The company supports pharmaceutical manufacturers, research laboratories, and analytical scientists working with different categories of pharmaceutical impurities and reference materials.
For researchers investigating Quetiapine EP Impurity N, Chemicea provides a relevant product reference through its dedicated product listing:
Chemicea's broader capabilities include:
Pharmaceutical impurity reference-standard development and supply.
Custom synthesis of pharmaceutical impurities and related compounds.
Research support for process impurities and degradation products.
Analytical characterization and impurity profiling solutions.
Development and supply of specialized reference materials for pharmaceutical research.
Through its chemistry-focused approach, Chemicea aims to support researchers and pharmaceutical organizations with materials and services relevant to analytical development and pharmaceutical quality investigations.
Frequently Asked Questions (FAQs)
1. What is Quetiapine EP Impurity N?
Quetiapine EP Impurity N is a specific quetiapine-related impurity associated with the European Pharmacopoeia impurity nomenclature. It has a distinct molecular structure containing a dibenzothiazepine moiety and two piperazine rings.
2. What is the CAS number of Quetiapine EP Impurity N?
The commonly reported CAS number for its free-base form is 1800291-86-4. Hydrochloride salt forms have separate CAS numbers.
3. What is the molecular formula of Quetiapine EP Impurity N?
Its commonly reported molecular formula is C₂₉H₄₁N₅O₃S, with a molecular weight of approximately 539.73 g/mol.
4. Which analytical techniques are used to characterize Quetiapine EP Impurity N?
HPLC, LC-MS, ¹H NMR, and ¹³C NMR are useful analytical techniques for investigating its chromatographic properties, molecular mass, and structural characteristics.
5. Why are impurity reference standards important for quetiapine analysis?
Reference standards help researchers establish compound identity, compare analytical responses, investigate related substances, and support analytical method development.
6. Where can researchers source Quetiapine EP Impurity N?
Researchers can explore Chemicea's dedicated Quetiapine EP Impurity N product page for product information and supply-related enquiries.
Conclusion
Quetiapine EP Impurity N is an important compound to consider in quetiapine-related impurity investigations because of its distinctive molecular structure and extended piperazine-containing side chain. Understanding its chemical characteristics and applying appropriate analytical techniques can help researchers investigate its identity and behaviour in pharmaceutical materials.
Techniques such as HPLC, LC-MS, and NMR spectroscopy provide complementary information for impurity characterization and analytical assessment. The availability of appropriately characterized reference materials further supports impurity identification, method development, and pharmaceutical quality-control investigations.
Chemicea Pharmaceuticals supports pharmaceutical research through its impurity reference standards, custom synthesis capabilities, and analytical solutions. These services are relevant to laboratories and pharmaceutical organizations seeking dependable resources for pharmaceutical impurity research.
Comments